Kestra Medical TechnologiesvsMerck & Company

KMTS and MRK stock compared: price, dividend, valuation and results, from SEC filings.

KMTS

Kestra Medical Technologies, Ltd.

$28.29

Value $1.7B

+0.07%
KMTS's page

MRK

Merck & Company, Inc.

$137.78

Value $341B

-3.90%
MRK's page

Kestra Medical Technologies (KMTS) has a market value of $1.7B and Merck & Company (MRK) $341B. Over the last year, with dividends, KMTS moved +12.7% and MRK +52.7%. Dividend yield: KMTS none, MRK 2.47%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    KMTS$1.7B

    MRK$341B

    MRK is 205 times KMTS

  • Revenue, 12 months

    KMTS$107M

    MRK$67.4B

    MRK is 631 times KMTS

  • Net income, 12 months

    KMTS-$150M

    MRK$2.5B

  • Operating margin

    KMTS-134.5%

    MRK–

  • ROIC

    KMTS-41.7%

    MRK3.9%

    45.6 points apart

  • P/E

    KMTS–

    MRK138.9

  • Dividend yield

    KMTS0.0%

    MRK2.5%

    2.5 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

KMTS+12.7%

MRK+52.8%

100150DecFebAprJunAugOct
Returns by period
PeriodKMTSWith dividendsMRKWith dividends
1 year since November 17, 2025+12.7%Price +12.7%+52.7%Price +48.4%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

KMTSKestra Medical TechnologiesMRKMerck & Company

Valuation

KMTSMRK
Valuation
Price$28.29$137.78
Market value$1.7B$341B
Enterprise value (EV)–$385B
P/E–138.9
P/E, 5-year median–14.8
P/B7.57.6
EV/EBIT–80.8
Free cash flow yield–4.3%

Results and growth

KMTSMRK
Results and growth
Revenue, 12 months$107M$67.4B
Net income, 12 months-$150M$2.5B
Free cash flow, 12 months-$123M$14.7B
Earnings per share, 12 months-$2.67$0.98
Revenue growth, year on year59.0%1.3%
Revenue growth a year, past+84.9%over 2 years+9.4%over 5 years
EPS growth a year, past–+21.2%over 5 years

Margins and returns on capital

KMTSMRK
Margins and returns on capital
Gross margin53.9%71.8%
Operating margin-134.5%–
Net margin-140.4%3.6%
ROIC-41.7%3.9%
ROE-67.0%5.2%

Balance sheet

KMTSMRK
Balance sheet
Cash$245M$9.7B
Total debt–$53.8B
Net debt / EBITDA–5.7
Interest cover-19.0×2.4×

Dividends and buybacks

KMTSMRK
Dividends and buybacks
Dividend yield–2.5%
Dividend per share, 12 months–$3.40
Dividend growth a year, past–+5.8%over 5 years
Buyback yield–1.5%
Shareholder yield–4.0%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: KMTS or MRK

Didn't find what you were looking for?

Ask us
Which is bigger, Kestra Medical Technologies or Merck & Company?

By market value, Merck & Company ($341B) is about 205.5 times Kestra Medical Technologies ($1.7B), at today's prices.

How did KMTS and MRK stock do over the last 1 years?

Since November 17, 2025, KMTS's price moved +12.7% and MRK's +48.4%. With dividends: KMTS +12.7% (+12.7% a year), MRK +52.7% (+52.7% a year). Past returns do not predict future ones.

Which pays the higher dividend, KMTS or MRK?

The dividend yield at today's price is none for Kestra Medical Technologies and 2.47% for Merck & Company. Over the last twelve months they paid – and $3.40 per share.

Which has the higher profit margins, Kestra Medical Technologies or Merck & Company?

Over the last twelve months, the net margin was -140.4% for Kestra Medical Technologies and 3.6% for Merck & Company, and the operating margin -134.5% and –. Revenue was $107M and $67.4B.

Which is the better investment, Kestra Medical Technologies or Merck & Company?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.